These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 12161490

  • 21. Discontinuation of growth hormone (GH) treatment: metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects. Swedish Study Group for Growth Hormone Treatment in Children.
    Johannsson G, Albertsson-Wikland K, Bengtsson BA.
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4516-24. PubMed ID: 10599711
    [Abstract] [Full Text] [Related]

  • 22. The influence of growth hormone (GH) therapy on cardiac performance in patients with childhood onset GH deficiency.
    Minczykowski A, Gryczynska M, Ziemnicka K, Czepczynski R, Sowinski J, Wysocki H.
    Growth Horm IGF Res; 2005 Apr; 15(2):156-64. PubMed ID: 15809020
    [Abstract] [Full Text] [Related]

  • 23. Comparative results of a 4-year study on cardiovascular parameters, lipid metabolism, body composition and bone mass between untreated and treated adult growth hormone deficient patients.
    Fideleff HL, Boquete HR, Stalldecker G, Giaccio AV, Sobrado PG.
    Growth Horm IGF Res; 2008 Aug; 18(4):318-24. PubMed ID: 18289903
    [Abstract] [Full Text] [Related]

  • 24. Growth hormone and the risk of atherosclerosis in growth hormone-deficient children.
    Binay C, Simsek E, Yıldırım A, Kosger P, Demiral M, Kılıç Z.
    Growth Horm IGF Res; 2015 Dec; 25(6):294-7. PubMed ID: 26296621
    [Abstract] [Full Text] [Related]

  • 25. Congenital growth hormone (GH) deficiency and atherosclerosis: effects of GH replacement in GH-naive adults.
    Oliveira JL, Aguiar-Oliveira MH, D'Oliveira A, Pereira RM, Oliveira CR, Farias CT, Barreto-Filho JA, Anjos-Andrade FD, Marques-Santos C, Nascimento-Junior AC, Alves EO, Oliveira FT, Campos VC, Ximenes R, Blackford A, Parmigiani G, Salvatori R.
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4664-70. PubMed ID: 17911170
    [Abstract] [Full Text] [Related]

  • 26. The effects of GH replacement therapy on cardiac morphology and function, exercise capacity and serum lipids in elderly patients with GH deficiency.
    Elgzyri T, Castenfors J, Hägg E, Backman C, Thorén M, Bramnert M.
    Clin Endocrinol (Oxf); 2004 Jul; 61(1):113-22. PubMed ID: 15212653
    [Abstract] [Full Text] [Related]

  • 27. The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults.
    Cuneo RC, Judd S, Wallace JD, Perry-Keene D, Burger H, Lim-Tio S, Strauss B, Stockigt J, Topliss D, Alford F, Hew L, Bode H, Conway A, Handelsman D, Dunn S, Boyages S, Cheung NW, Hurley D.
    J Clin Endocrinol Metab; 1998 Jan; 83(1):107-16. PubMed ID: 9435425
    [Abstract] [Full Text] [Related]

  • 28. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
    Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU, Bonert V, Dimaraki E, Stavrou S, Vance ML, Hayden D, Klibanski A.
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
    [Abstract] [Full Text] [Related]

  • 29. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board.
    Bengtsson BA, Abs R, Bennmarker H, Monson JP, Feldt-Rasmussen U, Hernberg-Stahl E, Westberg B, Wilton P, Wüster C.
    J Clin Endocrinol Metab; 1999 Nov; 84(11):3929-35. PubMed ID: 10566630
    [Abstract] [Full Text] [Related]

  • 30. Carotid artery intima-media thickness and lipid profile in adults with growth hormone deficiency after long-term growth hormone replacement.
    Soares DV, Spina LD, de Lima Oliveira Brasil RR, da Silva EM, Lobo PM, Salles E, Coeli CM, Conceição FL, Vaisman M.
    Metabolism; 2005 Mar; 54(3):321-9. PubMed ID: 15736109
    [Abstract] [Full Text] [Related]

  • 31. Impact of discontinuation of growth hormone treatment on lipids and weight status in adolescents.
    Rothermel J, Lass N, Bosse C, Reinehr T.
    J Pediatr Endocrinol Metab; 2017 Jul 26; 30(7):749-757. PubMed ID: 28672749
    [Abstract] [Full Text] [Related]

  • 32. Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency.
    Colao A, Di Somma C, Rota F, Pivonello R, Savanelli MC, Spiezia S, Lombardi G.
    J Clin Endocrinol Metab; 2005 Apr 26; 90(4):2056-62. PubMed ID: 15671089
    [Abstract] [Full Text] [Related]

  • 33. Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections.
    Amato G, Mazziotti G, Di Somma C, Lalli E, De Felice G, Conte M, Rotondi M, Pietrosante M, Lombardi G, Bellastella A, Carella C, Colao A.
    J Clin Endocrinol Metab; 2000 Oct 26; 85(10):3720-5. PubMed ID: 11061530
    [Abstract] [Full Text] [Related]

  • 34. Cluster of cardiometabolic risk factors in children with GH deficiency: a prospective, case-control study.
    Capalbo D, Mattace Raso G, Esposito A, Di Mase R, Barbieri F, Meli R, Bruzzese D, Salerno M.
    Clin Endocrinol (Oxf); 2014 Jun 26; 80(6):856-62. PubMed ID: 24372071
    [Abstract] [Full Text] [Related]

  • 35. Different effects of continuous and intermittent patterns of growth hormone administration on lipoprotein levels in growth hormone-deficient patients.
    Laursen T, Lemming L, Jørgensen JO, Klausen IC, Christiansen JS.
    Horm Res; 1998 Jun 26; 50(5):284-91. PubMed ID: 9873197
    [Abstract] [Full Text] [Related]

  • 36. Atherogenic lipoprotein phenotype and low-density lipoprotein size and subclasses in patients with growth hormone deficiency before and after short-term replacement therapy.
    Rizzo M, Trepp R, Berneis K, Christ ER.
    Eur J Endocrinol; 2007 Mar 26; 156(3):361-7. PubMed ID: 17322496
    [Abstract] [Full Text] [Related]

  • 37. Platelet hyperactivation in maintained growth hormone-deficient childhood patients after therapy withdrawal as a putative earlier marker of increased cardiovascular risk.
    Reis F, Campos MV, Bastos M, Almeida L, Lourenço M, Ferrer-Antunes CA, Palmeiro A, Santos-Dias JD, Mesquita JF, Carvalheiro M, Teixeira F.
    J Clin Endocrinol Metab; 2005 Jan 26; 90(1):98-105. PubMed ID: 15494463
    [Abstract] [Full Text] [Related]

  • 38. [Left ventricular mass and function in growth hormone deficient children and adolescents before and after one year of recombinant human growth hormone (GH) replacement therapy].
    Szczepańska Kostro J, Tołwińska J, Urban M, Głowińska B.
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2004 Jan 26; 10(2):75-80. PubMed ID: 15504309
    [Abstract] [Full Text] [Related]

  • 39. Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan's syndrome.
    Tanriverdi F, Unluhizarci K, Kula M, Guven M, Bayram F, Kelestimur F.
    Growth Horm IGF Res; 2005 Jun 26; 15(3):231-7. PubMed ID: 15921942
    [Abstract] [Full Text] [Related]

  • 40. One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults.
    Boguszewski CL, Meister LH, Zaninelli DC, Radominski RB.
    Eur J Endocrinol; 2005 Jan 26; 152(1):67-75. PubMed ID: 15762189
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.